In the most recent quarter, Commerzbank Aktiengesellschaft FI reduced its stake in AbbVie by 30.5%, selling 39,586 shares and ending the period with 90,102 shares valued at approximately $20.9 million. Meanwhile, Norges Bank established a new position during Q2 worth roughly $4.29 billion, and Laurel Wealth Advisors dramatically increased its holding by over 18,000%, acquiring 5.7 million shares for about $1.06 billion. Vanguard added 3.38 million shares (a 1.9% increase), raising its total to 177.3 million shares valued at $32.9 billion, while DZ BANK boosted its stake by 169.3%, purchasing 2.97 million additional shares worth $876.7 million. Overall, institutional ownership stands near 70.2%, underscoring strong professional interest in AbbVie’s long-term outlook.

AbbVie reported third-quarter revenue of $15.78 billion, up 9.1% year-over-year, and non-GAAP earnings per share of $1.86, beating consensus estimates by $0.09. The robust top-line growth was driven by continued strength in immunology and oncology franchises. Management issued fourth-quarter guidance of $3.320–3.360 in EPS and raised full-year projections to approximately $12.31, reflecting confidence in pipeline progress and the anticipated launch of new specialty therapies. The company’s net margin remains elevated at 4.0%, and return on equity exceeded 3,200%, demonstrating efficient capital deployment.

AbbVie announced a quarterly dividend of $1.73 per share, up from $1.64, marking an annualized payout of $6.92 and a yield of approximately 3.2%. The dividend will be paid to shareholders of record on January 16, with an ex-dividend date set for that same day. This represents a payout ratio of 524%, reflecting AbbVie’s commitment to returning capital to investors despite continued investment in R&D. The increase underscores the company’s confidence in generating stable free cash flow and supports its status as a core holding for income-oriented portfolios.

Analysts maintain a “Moderate Buy” consensus rating on AbbVie, with a consensus price target near $248. Recent research notes include Morgan Stanley’s overweight rating with a $269 target and BMO Capital Markets’ outperform view at $258. Two firms rate the stock as Strong Buy, thirteen as Buy and eight as Hold. The share valuation, based on a forward P/E of around 17 and a PEG ratio of 0.9, suggests modest upside, while the low beta (0.36) highlights defensive characteristics attractive to risk-averse investors.